Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 13;11(12):1359.
doi: 10.3390/jpm11121359.

Outcome of Critically Ill COVID-19 Patients According to the Setting of Corticosteroid Initiation-A Retrospective Observational Cohort Study

Affiliations

Outcome of Critically Ill COVID-19 Patients According to the Setting of Corticosteroid Initiation-A Retrospective Observational Cohort Study

Sebastian Voicu et al. J Pers Med. .

Abstract

(1) Background: Corticosteroids lower 28-day all-cause mortality in critically ill COVID-19 patients. However, the outcome of COVID-19 patients referred to the intensive care unit (ICU) for respiratory deterioration despite corticosteroids initiated during hospitalization before ICU admission has been poorly investigated. Our objective was to determine survival according to corticosteroid initiation setting. (2) Methods: We conducted a cohort study including all successive critically ill COVID-19 patients treated with corticosteroids and managed in our ICU. We compared survival, whether corticosteroids were initiated before (Cb-group) or after ICU admission (Ca-group), using a propensity score matching. (3) Results: Overall, 228 patients (67 years (56-74); 168M/60F; invasive mechanical ventilation on admission, 17%) were included with 63 patients in the Cb-group and 165 patients in the Ca-group. Survival to hospital discharge was 43% versus 69%, respectively (p = 0.001). In a multivariable analysis, factors associated with death were age (odds ratio, 1.07; 95%-confidence interval, (1.04-1.11); p < 0.0001), the sequential organ failure assessment (SOFA) score on ICU admission (1.30 (1.14-1.50); p = 0.0001) and corticosteroid initiation before ICU admission (2.64 (1.30-5.43); p = 0.007). No significant differences in outcome related to corticosteroid regimen were found. (4) Conclusions: Critically ill COVID-19 patients transferred to the ICU with deterioration despite corticosteroids initiated before admission have a less favorable outcome than patients receiving corticosteroids initiated after ICU admission.

Keywords: COVID-19; corticosteroid; dexamethasone; intensive care unit; mortality; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the study.
Figure 2
Figure 2
Survival to hospital discharge in the two critically ill COVID-19 groups according to the corticosteroid initiation setting, i.e., before versus after intensive care unit admission. Survivors are represented in blue, non-survivors in grey.

References

    1. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: A prospective cohort study. Intensive Care Med. 2021;47:60–73. doi: 10.1007/s00134-020-06294-x. - DOI - PMC - PubMed
    1. Galloway J.B., Norton S., Barker R.D., Brookes A., Carey I., Clarke B.D., Jina R., Reid C., Russell M.D., Sneep R., et al. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. J. Infect. 2020;81:282–288. doi: 10.1016/j.jinf.2020.05.064. - DOI - PMC - PubMed
    1. Torres Acosta M.A., Singer B.D. Pathogenesis of COVID-19-induced ARDS: Implications for an ageing population. Eur. Respir. J. 2020;56:2002049. doi: 10.1183/13993003.02049-2020. - DOI - PMC - PubMed
    1. RECOVERY Collaborative Group. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021;384:693–704. - PMC - PubMed
    1. Angus D.C., Derde L., Al-Beidh F., Annane D., Arabi Y., Beane A., van Bentum-Puijk W., Berry L., Bhimani Z., Bonten M., et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324:1317–1329. - PMC - PubMed

LinkOut - more resources